Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...

Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

Ultra-processed food consumption in obese adolescents is linked to insulin resistance and liver disease, stressing the need ...

The London-based biotechnology company said the non-dilutive funding will support its ongoing development of its lead gene therapy, GF-1002, for the treatment of metabolic associated steatohepatitis, ...

KOCHI: George (name changed), was 55-years-old when he was diagnosed with fatty liver. Since he was a teetotaller, he did not ...

Professor Ramou Njie made this disclosure recently during her presentation as part of activities marking liver cancer ...

SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for ...

Milk thistle, known for its silymarin content, is celebrated for protecting the liver against damage, reducing inflammation, ...

The study first used laboratory models of pulmonary TB to examine the changes happening within the liver during the early ...

A study has shown that tuberculosis disrupts glucose metabolism in the liver, potentially leading to diseases like diabetes.

In cases of pulmonary fibrosis attributable to interstitial lung disease, whether the aetiology is known or unknown, the ...

BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological ...